-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Lumos Pharma to Neutral, Lowers Price Target to $4.25

Benzinga·10/24/2024 18:53:43
Listen to the news
HC Wainwright & Co. analyst Edward White downgrades Lumos Pharma (NASDAQ:LUMO) from Buy to Neutral and lowers the price target from $28 to $4.25.